Division of Crop Genetics and Breeding, Crop Research Institute, Prague, 6-Ruzyně, Czechia.
Plant Foods Hum Nutr. 2020 Jun;75(2):131-141. doi: 10.1007/s11130-020-00800-8.
Oats represent a promising alternative to small-grain cereals from Triticeae group (wheat, barley, rye) for persons suffering from any form of gluten intolerance, especially celiac disease (CD), since oat-specific prolamins avenins reveal generally lower gluten content and immunoreactivity. Recent studies on avenin molecular structure revealed large genetic variability in avenin sequences affecting the spectrum of gluten peptides produced by hydrolases in human digestive tract. The aim of the present review is to summarise recent knowledge obtained in laboratory studies focused on the effect of avenin-derived peptides on reactivity of crucial components of human immune system such as dendritic cells (DC) and T-cells. The other part of the review summarises the results of clinical studies with CD patients including oat products in their diet. Since different clinical studies revealed contradictory results regarding potential safety of oats for CD patients, the focus has to be directed at genetic variability in oat avenins. Identification of avenin isoforms with minimum CD immunoreactivity will open up ways leading to designing novel oat cultivars suitable for CD patients. Knowledge on immunoreactivity of gluten peptides together with breeding new oat cultivars revealing minimum avenin immunoreactivity with respect to CD as well as application of food processing technologies leading to gluten content reduction should result in development of gluten-free oats safe for celiacs.
燕麦是从小麦族(小麦、大麦、黑麦)的小谷物中提取的一种很有前途的替代品,适用于任何形式的不耐受谷蛋白的人群,尤其是乳糜泻(CD)患者,因为燕麦特有的醇溶蛋白 avenins 通常显示出较低的谷蛋白含量和免疫原性。最近对 avenin 分子结构的研究揭示了 avenin 序列的遗传多样性很大,这会影响到人类消化道中水解酶产生的谷蛋白肽的谱。本综述的目的是总结最近在实验室研究中获得的知识,这些研究集中在 avenin 衍生肽对人类免疫系统关键成分(如树突状细胞(DC)和 T 细胞)反应的影响。综述的另一部分总结了对 CD 患者进行的临床研究的结果,包括饮食中含有燕麦产品。由于不同的临床研究对燕麦对 CD 患者的潜在安全性得出了相互矛盾的结果,因此必须关注燕麦 avenins 的遗传多样性。鉴定出最小 CD 免疫反应性的 avenin 同工型将为设计适合 CD 患者的新型燕麦品种开辟道路。了解谷蛋白肽的免疫原性,以及培育新的燕麦品种,使其对 CD 具有最小的 avenin 免疫原性,并应用可降低谷蛋白含量的食品加工技术,应有助于开发出对乳糜泻患者安全的无麸质燕麦。